Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone (non‑benzodiazepine hypnotic) presented as a tablet for oral use. It treats insomnia by helping adults fall asleep and stay asleep, and is indicated for short‑term management of difficulty initiating or maintaining sleep in patients with primary insomnia.

GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides reliable logistics for regulated medicines. Imovane is manufactured under strict GMP conditions to ensure product integrity.

Zopiclone is a non‑benzodiazepine hypnotic that acts on the central nervous system to improve sleep quality.

- Primary insomnia: improves sleep onset and maintenance in adults with chronic difficulty sleeping. - Sleep onset insomnia: shortens the time needed to fall asleep after bedtime. - Sleep maintenance insomnia: reduces the number of nocturnal awakenings and prolongs total sleep time. - Transient insomnia due to jet lag: helps adjust sleep pattern during travel. - Insomnia associated with psychiatric conditions: supports sleep while other treatments address the underlying disorder.

Zopiclone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Bitter taste: unpleasant metallic sensation in the mouth. - Drowsiness: feeling of sleepiness during daytime. - Dry mouth: reduced salivation leading to thirst. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Complex sleep behaviours: activities such as sleepwalking or sleep‑driving performed while not fully awake. - Allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Depression or mood changes: emergence of low mood, anxiety, or suicidal thoughts. - Memory impairment or amnesia: difficulty recalling events after waking.

Before prescribing Zopiclone, clinicians should evaluate several safety considerations to minimise risks.

- Assess sleep hygiene: evaluate non‑pharmacologic measures before initiating therapy. - Avoid alcohol: concurrent consumption may intensify sedation and respiratory depression. - Elderly patients: use the lowest effective dose and monitor for falls or confusion. - Short‑term use: limit treatment to two weeks or less to reduce dependence potential. - Pregnancy and lactation: discuss potential risks with the prescriber and consider alternatives. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Zopiclone can interact with other medicines, altering its sedative effect or plasma concentration.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression leading to profound sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase Zopiclone levels and risk of toxicity. - Opioids: combined use may cause enhanced respiratory depression and profound sedation.

Moderate Interactions (Monitor Closely): - Other CNS depressants (e.g., antihistamines, muscle relaxants): may increase overall sedation. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce Zopiclone effectiveness by lowering plasma concentrations. - Certain antidepressants (e.g., fluoxetine, sertraline): possible pharmacodynamic interaction affecting sleep architecture.